Details der Publikation - Study to evaluate efficacy and safety of Benralizumab in reducing Oral Corticosteroid use in adult patients with severe asthma.

Study to evaluate efficacy and safety of Benralizumab in reducing Oral Corticosteroid use in adult patients with severe asthma. : A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid plus Long acting ß2 Agonist and Chronic Oral Corticosteroid Therapy (PONENTE) - PONENTE

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Severe Eosinophilic Asthma MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 18-02-2019, Last updated: 2023-06-29

ICTRP ID:	EUCTR2018-000170-30-GB D3250C00065 2018-000170-30-DE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO005926041

Internformat


LEADER	01000caa a22002652 4500
001	WHO005926041
003	DE-627
005	20230629100636.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO005926041
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2018-000170-30-GB
035			\|a (UBBS_Klinische_Studien_WHO)D3250C00065
035			\|a (UBBS_Klinische_Studien_WHO)2018-000170-30-DE
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Study to evaluate efficacy and safety of Benralizumab in reducing Oral Corticosteroid use in adult patients with severe asthma. \|b A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid plus Long acting ß2 Agonist and Chronic Oral Corticosteroid Therapy (PONENTE) - PONENTE
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 18-02-2019, Last updated: 2023-06-29
650		4	\|a Medical Condition: Severe Eosinophilic Asthma MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 21. Juni
773	1	8	\|g year:2023 \|g day:21 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000170-30 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 21 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände